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Abstract
Purpose: To describe the clinicopathological and morphological features of gastrointestinal stromal tumours (GISTs) 
on multi-detector computed tomography (MDCT).
Material and methods: MDCT (plain and post contrast) images of 25 confirmed cases of GISTs were retrospectively 
evaluated from our hospital database. The images were analysed for the location, size, growth pattern, attenuation 
pattern, relation to adjacent structures, presence or absence of ulceration, calcification, metastases, lymphadenopathy, 
and for any complications such as haemorrhage, intestinal obstruction, etc. Institutional Ethics Committee clearance 
was obtained prior to the commencement of the study. Statistics used included percentage frequency.
Results: Our study group comprised 14 males and 11 females. The mean age of our study population was 60 years 
(age range: 40 to 82 years). The mean tumour size was 11.7 cm. The stomach and small bowel accounted for 76% of 
the primary tumour site. The commonest imaging appearance of GIST observed in our study was that of an exo-
phytic mass (76%) with a heterogenous pattern of enhancement (96%) with intratumoural necrosis (76%). MDCT 
demonstrated complications in three patients (12%). Six patients presented with metastatic foci (five to the liver and 
one to the lung), while lymphadenopathy was observed in five patients (20%). Associated complications included 
intestinal obstruction (8%) and retrogastric haematoma (4%). Incidental findings included uterine fibroid (n = 1), 
ovarian dermoid (n = 1), and chronic pancreatitis (n = 1).
Conclusions: GISTs are predominantly large tumours with a well circumscribed and exophytic pattern on MDCT, with 
or without cystic/necrotic areas, and they mostly show a heterogenous pattern of enhancement on post-contrast 
administration.
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Introduction 
Gastrointestinal stromal tumours (GISTs) are rare, but 
they are the most common mesenchymal tumours. GISTs 
may have their origin anywhere in the gastrointestinal 
tract (GIT) from the mouth to the rectum, or even in the 
mesentery or omentum. Ninety per cent of GISTs show 
a strong immunohistochemical staining for KIT, a tyrosi-
nase kinase growth factor receptor, making them different 
from other mesenchymal tumours in pathology. Benign 
GISTs may be discovered incidentally and are usually 
excised. Contrast-enhanced multi-detector computed to-
mography (MDCT) is the most commonly used modality 
for initial evaluation and staging of GISTs. While 18-FDG 
positron emission tomography-computed tomography 
(PET-CT) has emerged as the gold standard for follow-up 
and evaluation of treatment response. The intention of our 
study is to evaluate GIST for its anatomical and patholog-
ical features on MDCT, as well as to highlight the role of 
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imaging in the detection, characterisation, and treatment 
response evaluation of GISTs [1].
Material and methods
MDCT images of 25 patients with GIST confirmed by 
a combination of histopathology and immunochemistry 
obtained over a period of four years, from March 2012 to 
March 2016, were retrospectively evaluated from our hos-
pital database. All the patients underwent MDCT evalua-
tion on a GE Bright Speed 16-Slice MDCT scanner. Initial 
plain (non-contrast) abdominal images were acquired to 
look for haemorrhage or calcification. Post-contrast im-
ages were obtained after intravenous administration of io-
promide (300 mg I/ml, Ultravist® 300; Bayer HealthCare 
Pharmaceuticals, San Francisco, CA) injected at the rate 
of 3 ml/s with the help of a Mallinckrodt pressure injector. 
Arterial and porto-venous phase images were acquired at 
18-22 s and 60-65 s, respectively. 3D reconstruction using 
thin sections (1 mm) were performed in coronal and sag-
ittal planes for better depiction of the lesion and its extent 
and involvement of adjacent structures. The images were 
reviewed on a commercially available workstation.
In those patients who underwent positive contrast 
CT enterography, patients were kept nil per os for about 
4-6 hours prior to ingestion of oral contrast. Positive con-
trast containing 65% meglumine diatrizoate (20 ml dis-
solved in 1500 ml of water) was orally consumed by the 
patient. About 1200 ml was consumed over a duration 
30-45 minutes, and the remaining 300 ml about 10 minutes 
prior to commencement of the scan. In order to obtain a uni-
form distention of the small bowel, patients were required 
to consume about 150 ml of the contrast mixture every 
5 minutes for 50-55 minutes. Imaging was performed about 
one hour post consumption of the oral contrast mixture.
Detailed clinical and histopathological data were 
obtained from the hospital database, including patients’ 
demographics such as sex, age, presenting clinical symp-
toms, etc. The MDCT images were assessed for tumour 
size, origin, location of the GIT involved by the tumour, 
tumour attenuation pattern on plain and post contrast ad-
ministration, presence or absence of ulceration, relation-
ship with adjacent organs and structures, presence or ab-
sence of metastases and/or lymphadenopathy, presence of 
any ancillary findings or complications such as intestinal 
obstruction, ascites, tumour bowel fistula, intraperitoneal 
rupture, etc., and for any additional incidental findings. 
Institutional Ethics Committee approval was obtained 
prior to commencement of the study. Statistical analysis 
involved percentage frequency.
Results
Of the 25 patients evaluated, 14 were males and 11 were 
females. The mean age of our study population was 
60 years, with the youngest being 40 and oldest being 
82 years old. The most common presenting symptom 
was abdominal pain (Figure 1). The primary tumour sites 
have been summarised in Table 1 and compared to two 
recent studies. The stomach and small bowel accounted 
for 76% of the primary tumour location in our study. 
The mean tumour size was 11.7 cm. Nineteen patients 
(76%) presented with an exophytic growth pattern on 
imaging, while a combination of exophytic-endophytic 
component (Figure 2) was seen in two cases (8%), and the 
remaining two cases presented as wall thickening involv-
ing the stomach (Figure 3) and duodenum, respectively. 
Among the non-gastric GISTs, superior mesenteric artery 
formed the bulk (45.8%) of their arterial supply. In six of 
the cases, the vascular supply could not be identified on 
MDCT. Except for one case of GIST, which showed mini-
mal enhancement, all the rest, i.e. 24 cases (96%), showed 
heterogenous enhancement. Nineteen cases (76%) had 
necrosis (< Hounsfield units), while intratumoural haem-
orrhage was seen in only one case (4%). None of the cases 
had calcification. Mucosal ulceration was observed in five 
patients (20%). At presentation, metastatic foci were seen 
in six patients; five in the liver (Figure 4) and one in the 
right lung (Table 2). The secondary liver lesions showed 
heterogenous enhancement on post contrast adminis-
tration. Lymphadenopathy (Figure 5) was observed in 
10 cases (40%), mostly in the coeliac and para-aortic re-
gion. Ascites (Figure 6) were seen in only eight cases 
(32%), while peritoneal deposits were seen in three of our 






















Table 1. A summary of the various primary tumour sites of gastrointestinal 
stromal tumours (GISTs) in the present study vs. other studies
Primary site Our study
(n = 25)
Burkill et al. [5]
(n = 116)
Levy et al. [17]
(n = 64)
Oesophagus 0 0 1 (2%)
Stomach 7 (28%) 43 (37%) 28 (44%)
Small Bowel 12 (48%) 49 (42%) 27 (42%)
Large Bowel 2 (8%) 13 (11%) 7 (11%)
Peritoneum 0 0 0
Other/Unknown 4 (16%) 11 (9%) 1 (2%)
Others: GISTs arising from omentum, mesentery, retroperitoneum, etc.
Unknown: tumour origin sites that could not be determined on imaging.
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cases. Associated complications (Figure 7) in our study in-
cluded-intestinal obstruction (n = 2, 8%) and retrogastric 
haematoma (n = 1, 4.2%). Incidental findings in our study 
included-uterine fibroid (n = 1), right ovarian dermoid 
(n = 1), and chronic pancreatitis (n = 1). A summary of the 
various morphological and clinic-pathological spectrum of 
GISTs in our study population is outlined in Table 3.
Figure 2. Post-contrast coronal (A) and sagittal (B) reformatted computed tomography images showing a gastric gastrointestinal stromal tumour with 
an exophytic (arrow) and an endophytic (arrowhead) component
A B
Figure 3. Post contrast axial computed tomography, porto-venous (A), and delayed phase with oral contrast (B) images showing a gastrointestinal stromal 
tumour presenting as a generalised wall thickening of the stomach
A B
Figure 4. Post-contrast axial computed tomography image of a malignant 
gastric gastrointestinal stromal tumour in a 60-year-old female patient with 
metastases to the liver
Table 2. Distribution of metastases in our study population
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Discussion
Gastrointestinal stromal tumours are rare but are the 
most common mesenchymal tumours [1]. The term GIST 
was first used by Mazur and Clark in 1983 [2]. These tu-
mours account for 0.1% to 3% of all gastrointestinal ne-
oplasms and 5-7% of sarcomas [3]. These nonepithelial 
tumours arise from the muscularis propria of the GIT 
and are believed to originate from the interstitial cells 
of Cajal – a pluripotent mesenchymal stem cell that acts 
as a pacemaker for controlling motility. GISTs can occur 
anywhere along the GIT, i.e. from the oral cavity to the 
rectum. The most common locations for the tumours are 
the stomach (60% of all GISTs), small bowel (30%), colon 
and rectum (5%), and oesophagus (< 1%). GISTs may also 
arise as a primary tumour of the omentum, mesentery, 
or retroperitoneum. These tumours account for 20% of 
all small bowel neoplasms and 0.2 to 1% of all colorectal 
tumours, have no sex predilection, and mostly occur in 
middle-aged and elderly patients [4,5]. Their incidence 
among children and young adults is rare and is some-
times associated with familial or inherited conditions like 
neurofibromatosis type-1, Carney triad (gastric GIST, pul-
monary chondroma, and paraganglioma), Carney-Stra-
takis syndrome (gastric GIST and paraganglioma), and 
familial GIST syndrome. These inherited forms of GIST 
tend to have a female preponderance, unlike the sporadic 
variety, which has no sex preponderance [6,7]. During the 
early stages, patients may be asymptomatic or have min-
imal symptoms and hence go undetected. However, by 
the time patients present with symptoms these tumours 
have grown to a considerable size with spread to other 
organs [8]. Clinical symptoms mostly depend on the size 
and site of the lesion, with the most common symptom 
being bleeding into the bowel or abdominal cavity sec-
ondary to ulceration of the tumour mucosa. Patients can 
Figure 5. Post contrast axial computed tomography sections, porto-venous (A) and delayed phase with oral contrast (B) images showing a duodenal 
gastrointestinal stromal tumour with lymphadenopathy
A B
Figure 6. An exophytic gastric gastrointestinal stromal tumour in a 79-year-old male patient with ascites
A B
Rishi Philip Mathew, Joseph Vinod Xavier, Sandeep M Babukumar et al.  
e614 © Pol J Radiol 2018; 83: e610-e618
also present with anaemia due to occult bleeding. Other 
symptoms include- nausea, vomiting, abdominal pain, 
abdominal mass, abdominal distention, obstructive jaun-
dice, constipation or diarrhoea, frequent urination, and 
fatigue. Twenty-five per cent of all GISTs are discovered 
incidentally during imaging or surgery, and some of them 
(≤ 5%) are found during autopsy [7,9,10].
Genetics
Histologically GIST can be classified as spindle cell (most 
common type: 75%), epithelioid, or pleomorphic mesen-
Figure 7. Scout (A) and coronal (B) reformatted post contrast computed tomography images of a 75-year-old male patient with secondary small bowel 
obstruction due an ileal gastrointestinal stromal tumour
A B
Table 3. A summary of the morphological and clinicopathological spectrum 
of GIST in our study population
Characteristics Findings
Males vs. females (years) 14 vs. 11
Mean age (years) 60 (range: 40-82)
Mean tumour size (largest 
dimension) (cm)
11.4 (range: 3.5-20)
Symptoms at presentation All patients symptomatic  
(abdominal pain being  
the most common symptom)
Mean tumour size (cm) 11.7
Most common primary 
tumour site location
Stomach and small bowel (76%)
Histological subtype Spindle cell (96%), epithelioid (4%)
Benign vs. malignant 19 (76%) vs. 6 (24%)
Tumour necrosis 19/25 (76%)
Metastases 6/25 (24%)
Metastases site Liver (n = 5) and lung (n = 1)
Lymphadenopathy 5/25 (25%)
Ascites 8/25 (32%)
Associated complications Intestinal obstruction (n = 2) and 
retro-gastric haematoma (n = 1)
Incidental findings Ovarian dermoid (n = 1), pancreatitis 
(n = 1), uterine fibroid (n = 1)
Figure 8. Spindle cells arranged in fascicles and showing mild pleomor-
phism and mitotic activity
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chymal tumours of the GI tract (Figure 8). All of them 
express a CD117 stem cell factor receptor called KIT 
protein, which can be detected immunohistochemically, 
which forms the key to the diagnosis of a GIST [1,11]. 
KIT is a tyrosine kinase (type 3) receptor that helps in 
the development of melanocytes, germ cells, mast cells, 
haematopoietic stem cells, interstitial cells of Cajal, and 
the pacemaker cells of the GI tract that GIST cells most 
closely resemble. 80-90% of all GIST show KIT or PDG-
FRA mutations. Nearly 80% of patients with GIST tend 
to show treatment response following administration of 
imatinib mesylate (Gleevec; Novartis Pharmaceutical 
Corp.), formerly known as STI-571, which is a targeted 
KIT tyrosine kinase inhibitor and used for the systemic 
treatment of GIST [12,13]. 
In sporadic GISTs, four different areas of KIT mu-
tations have been identified, and in decreasing order of 
frequency they are: exon 11, exon 9, exon 13, and exon 
17. The majority of the KIT mutant proteins are imatinib 
sensitive. However, exon 17 KIT mutants are primarily 
resistant, and exon 9 KIT mutants are less sensitive as 
compared to exon 11 mutants. Gastric GISTs with epi-
thelioid morphology have a strong affinity for PDGFRA 
mutations, and three different areas of PDGFRA muta-
tions have been found in GISTs. In decreasing order of 
frequency, they include: exon 18, exon 12, and exon 14. 
The majority of the PDGFRA mutations occur in exon 
18. Some patients who respond to imatinib ultimately 
develope metastases with drug resistance, secondary to 
imatinib-resistant mutations in KIT or PDGFRA tyrosine 
kinase (TK1 and TK2) domains. In recent years, several 
unique secondary point mutations have been detected and 
shown to affect the same gene allele as primary mutations 
[13]. In those patients with a KIT-negative GIST, it is rec-
ommended to perform a genotype assay to identify the 
mutational status of both the KIT and PDGFRA genes in 
order to establish a deﬁnitive diagnosis [14]. Another im-
munohistochemical marker that may be positive in GIST 
is S-100, while markers such as alpha smooth muscle anti-
gen (α-SMA) and vimentin are usually negative [15]. 
The majority of the GISTs are benign (70-80%). GISTs 
of the stomach tend to be benign, where they outnum-
ber malignant GISTs by a ratio of 3-5 : 1. Smaller GISTs 
(< 2 cm) are also considered benign with a low recurrence 
rate. However, no GIST can be truly labelled as a benign 
lesion as they tend to have a spectrum of presentation de-
pending on the anatomic site, tumour size, and mitotic 
frequency [13-15].
Imaging of GISTs
With advances in treatment resulting in prolonged surviv-
al of patients diagnosed with GIST, imaging plays not only 
a crucial role in the early detection and diagnosis but also 
for monitoring the treatment and disease progression. On 
plain radiographs, an incidental soft tissue mass, rarely 
with calcifications, displacing the gastric air shadow or 
associated small bowel dilatation may be seen [16]. 
Barium studies have a limited role in the evaluation 
of GISTs and may show an intraluminal or submucosal 
well-circumscribed mass with margins forming an obtuse 
or right angle with the stomach wall, with the possibility 
of some luminal irregularity or focal area of ulceration. 
These lesions may also have a mass effect with or without 
cavity/fistula formations [17]. 
On ultrasound, GISTs commonly presents as a large 
abdominal mass with heterogeneous echotexture with 
or without necrosis. Often the site of origin may be diffi-
cult to determine on ultrasound [18]. A common site for 
metastases of malignant GIST is the liver, and the lesions 
are usually hypoechoic compared to the liver parenchy-
ma. Contrast enhanced ultrasonography (CEUS) may be 
useful for identifying the presence of viable neoplastic 
tissue in the primary tumour as well as in demonstrating 
liver metastases [19]. Endoscopic ultrasound is a useful 
imaging tool for diagnosing small incidental submucosal 
GISTs, by clearly defining their gut wall layers and allow-
ing biopsy confirmation [20]. 
Computed tomography is currently the imaging mo-
dality of choice both for diagnosis and initial staging 
of GISTs. CT appearance of GISTs depends on the size, 
tumour aggressiveness, and time of presentation of the 
disease. These neoplasms display an exophytic growth 
pattern because they involve the outer muscular layer 
and hence the commonest appearance on imaging is that 
of a lesion arising from the GIT and protruding into the 
abdominal cavity. Primary GISTs are mostly large, hyper-
vascular, enhancing masses following contrast administra-
tion, with a heterogenous appearance secondary to necro-
sis, haemorrhage, or cystic degeneration. Ulceration and 
fistulisation are common feature of GITSs, and often tu-
mour vessels may be seen within the mass. The majority of 
GISTs are well-defined, extraluminal, or intramural mass-
es with nearly 50% of cases having mucosal ulcerations on 
the luminal surface [17,21,22]. Small GISTs (measuring 
< 5 cm) can be endoluminal and polypoidal in appearance 
with well-defined, smooth-walled, homogenous soft-tis-
sue lesions involving the gastric wall or the small bowel 
with an intraluminal component and show homogeneous 
enhancement after contrast. Large GISTs may be well- or 
ill-defined, have a heterogenous density on both plain as 
well as contrast studies with an intraluminal/extraluminal 
component, displacing/invading adjacent structures. Tu-
mours measuring > 6 cm commonly demonstrate central 
necrosis or haemorrhage, while wall calcifications are very 
rare. After contrast administration, strong peripheral en-
hancement is seen due to the presence of viable neoplastic 
tissue [22,23]. Large GISTs may also have a ‘dumbbell’ ap-
pearance, due to an intra- and extra-luminal component, 
or present as extraluminal mass, making identification of 
its origin extremely difficult. In such situations multipla-
nar reconstructed images may prove useful [19,20,24]. 
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Large GISTs due to profound haemorrhage or necrosis 
can form large cystic masses or cavities, which may com-
municate with the lumen and contain air, air-fluid levels, 
or oral contrast medium [25]. About 50% of all GISTs 
may metastasise [26]. CT features suggestive of malig-
nancy include: lesions measuring > 5 cm in diameter, ir-
regular surface, ill-defined margins, invasion of adjacent 
structures, heterogeneous contrast enhancement, hepatic 
metastases, and peritoneal dissemination. The most com-
mon sites for metastases are the liver and peritoneum, by 
hematogenous and peritoneal spread, respectively. Rarely, 
GISTs may metastasise to the soft tissue, lungs and pleura. 
However, metastases to the lymph nodes are extremely rare 
compared to gastrointestinal adenocarcinoma. Ascites may 
be a feature on CT when the tumour has invaded the omen-
tum or peritoneal space [17,25,27]. Dual-phase CT is supe-
rior to single-phase venous studies because there is a possi-
bility that hypervascular lesions may be missed, as well as for 
evaluating the disease response to Gleevec therapy and for 
identifying relapse. Mesenteric metastases are seen better on 
CT than on magnetic resonance imaging (MRI). 
MRI is useful for planning surgery in those patients 
with a GIST localised to the rectum, for evaluating inde-
terminate liver lesions on CT and in those patients where 
CT is contraindicated. MRI may also be used as an adjunct 
to CT in the evaluation of large GISTs [15,28]. The signal 
intensity of GISTs on MRI varies greatly and depends on 
the extent of necrosis and haemorrhage. The solid por-
tions of GISTs are generally hypointense on T1-weighted 
images (T1-WI), hyperintense on T2-weighted images 
(T2-WI), and show enhancement after administration 
of contrast, while areas of haemorrhage within the lesion 
may appear hypo- or hyper-intense on T1-WI/T2-WI, de-
pending on the age of the bleed [16,29].
Diffusion-weighted imaging (DWI) may be useful to 
assess response to treatment, which is indicated by an in-
crease in ADC values compared to pre-treatment values 
and can be seen about one week after initiation of im-
atinib therapy [30]. Current developments in DWI may 
also provide new prognostic biomarkers and indicators 
of response to targeted tumour molecular therapy [31].
18-FDG-PET-CT is the imaging modality of choice for 
GIST staging, follow-up, as well as for evaluating therapy 
response [32]. Patients who respond to imatinib demon-
strate a marked reduction in the glycolytic metabolism of 
GISTs which can be identified easily by F18-FDG-PET. 
This response can be seen one month after initiating ther-
apy, and as early as 24 hours post treatment initiation [33]. 
18-FDG PET is also useful when CT findings are ambig-
uous. For example, patients with a primary GIST with 
hepatic metastases during imatinib therapy may develop 
new lesions in the liver. Traditionally, as per the criteria of 
SWOG (Southwest Oncology Group), the WHO (World 
Health Organisation), and RECIST (Response Evaluation 
Criteria in Solid Tumours), these patients would be la-
belled under disease progression rather than as response 
to therapy. However, in reality these patients may in fact 
be responding to treatment. This was observed by Joensuu 
et al. [34] in the first ever GIST patient treated with im-
atinib, when the metastatic hepatic lesion in the index pa-
tient became hypodense and showed a reduction in con-
trast enhancement on MRI. Similar findings have since 
been reported on CT [35]. Another advantage of 18-FDG 
PET is in identifying lesions with CT findings suggest-
ing of tumour growth, when in fact the increase in size is 
due to intratumoural haemorrhage or to tumour swelling 
unrelated to disease progression. In both the above-men-
tioned circumstances 18-FDG PET will be negative, con-
firming the patient’s response to treatment [35].
Management of GISTs and recent advances
Complete surgical resection is the treatment for GISTs 
> 2 cm localised to the stomach and for extra-gastric GISTs 
of any size. Nearly 60% of all patients with GISTs are cured 
by surgery [36]. When adjacent organs become involved 
a multivisceral resection may be needed, such as in the 
case of duodenal GISTs that may require a pancreatodu-
odenectomy. However, in such patients, tumour shrinkage 
by neoadjuvant imatinib treatment should be done in order 
to allow resection with the possibility of organ preserving 
surgery [37]. Systemic lymph node dissection is usually not 
required as these tumours very rarely metastasize to region-
al lymph nodes [38]. Laparoscopic surgery is best advised 
for easily accessible lesions and not recommended for le-
sions > 5 cm in diameter [39]. Transluminal endoscopic 
surgery has also been described for small GISTs [40], but 
the procedure carries the risk of incomplete resection, and 
as long as techniques for postinterventional gastric wall clo-
sure are not standardised, such kinds of surgical procedures 
must be considered as experimental [41]. As far as adjuvant 
therapy is concerned, current guidelines of the European 
Society for Medical Oncology (ESMO) and National Com-
prehensive Cancer Network (NCCN) state that a minimum 
of three years of adjuvant imatinib is the standard treatment 
for patients with a high risk of relapse following primary 
GIST resection [42]. Novel agents currently under inves-
tigation for GIST treatment include: TKIs (e.g. Ponatinib), 
immunomodulating agents, heat shock protein inhibitors, 
a phosphoinositide 3-kinase inhibitor, and an insulin-like 
growth factor 1 inhibitor (e.g. linsitinib) [43,44]. Interven-
tional procedures such as radio-frequency ablation (RFA) 
[45], transarterial yttrium-90 radio-embolisation [46], and 
transarterial chemoembolisation (TACE) [47] have all been 
attempted in patients with GIST metastases, but most of 
these studies were retrospective and included a limited 
number of patients.
Differential diagnosis
Differential diagnosis for GISTs depends on their location. 
Differentials for GISTs include: leiomyoma, leiomyosar-
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coma, schwannoma, neurofibroma, adenocarcinoma, and 
carcinoids [48].
Conclusions
MDCT is the imaging modality of choice for the char-
acterisation and diagnosis of GISTs. Radiologists need 
to be aware of all the imaging characteristics of GISTs, 
which may help to identify benign from malignant GISTs. 
A large exophytic, eccentrically located gastric or bowel 
wall lesion, which is well circumscribed with or without 
necrosis and lack of lymphadenopathy, should raise the 
suspicion of a gastrointestinal stromal tumour. Our study 
showed that malignant GISTs tend to be larger and have 
ulcerations. Peritoneal implants and metastases to differ-
ent organs, especially the liver, and lymphadenopathy, al-
though rare, were additional features of malignant GISTs.
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